Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2
63
about 9.1 years
12+
3 sites in MD, OH, TX
What this study is about
This trial is testing azacitidine and enasidenib as a treatment for patients with IDH2-mutant myelodysplastic syndrome. The goal is to assess the safety and effectiveness of these medications in stopping cancer cell growth.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Quality-of-Life Assessment
- 2.Take Azacitidine
- 3.Take Enasidenib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
azacitidine, enasidenib
injection, subcutaneous, oral (Oral Tablet)
Primary: Incidence of adverse events, Overall response rate
Secondary: Event-free survival (EFS), Overall survival (OS)
Musculoskeletal, Oncology